MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:
THERACLION (Alternext, FR0010120402 - ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that it has reached an important milestone with the realization of the 1,000th treatment by echotherapy, along with the evolution of the ownership distribution of its capital.
More than 1,000 patients benefited from echotherapy
“During May 2017, the one thousandth Echopulse treatment was performed. This symbolic milestone reflects treatment volume across all indications.” Half were performed over the past 18 months, illustrating strong growth in treatment volume and device utilization. This growth is made possible by the adoption of this non-invasive alternative by several renowned medical centers in Europe and Asia. The proportion of the number of treatments per indication has changed considerably over time, validating the strategy defined by Theraclion in recent years. Thus, during the period 2014-2015, 20% of the treatments by echotherapy concerned thyroid nodules, while today 70% of treatments carried out relate to this indication (period 2016-2017).
It should also be noted that no fewer than 6 scientific papers reviewed by a peer review committee were published in 2017, bringing the total number of publications on echotherapy to 15. All these publications showed that echotherapy is an effective and safe non-invasive alternative in the treatment of breast fibroadenomas and benign thyroid nodules.
“We are pleased to announce that we have completed the 1,000th treatment by echotherapy. This marks an important milestone for Theraclion and demonstrates that echotherapy is no longer a technology in development but has entered clinical practice, providing many patients with access to a non-invasive therapeutic solution. In addition, echotherapy has been shown to be effective and safe for the treatment of breast fibroadenomas and thyroid nodules in more than 15 scientific articles published in international journals,” explains David Caumartin, CEO of Theraclion.
Changes in the breakdown of Theraclion shareholding
On May 16, 2017, Truffle Capital declared that, on January 9, 2017, it had crossed the threshold of 50% of the voting rights of Theraclion by selling securities on the market.
To the knowledge of the Company, Truffle had 47.7% of voting rights as of May 11, 2017, against 53.8% as of August 20, 2016. Funds managed by Truffle Capital have been the historic shareholder of Theraclion since its creation 13 years ago. Truffle Capital’s mission is to support the launch of innovative start-ups. Truffle Capital remains Theraclion’s key shareholder, which continues to expand and grow in maturity.
As of May 11, 2017 and to the knowledge of the Company, the Company’s share capital is as follows:
| As of May 11, 2017 | Number of shares making up the share capital | % of ownership | Number of theoretical voting rights | % of theoretical voting rights | ||||
| Sub-total funds managed by Truffle Capital | 2,299,028 | 35.7% | 4,127,364 | 47.7% | ||||
| Furui | 1,208,651 | 18.8% | 1,208,651 | 14.0% | ||||
| Other registered shares | 414,772 | 6.4% | 799,243 | 9.2% | ||||
| Treasury shares | 15,323 | 0.2% | 15,323 | 0.2% | ||||
| Other Public | 2,503,255 | 38.9% | 2,503,255 | 28.9% | ||||
| Total | 6 441 029 | 100.0% | 8 653 836 | 100.0% | ||||
As of August 20, 2016, the ownership and distribution of the Company’s capital was as follows:
| As of August 20, 2016 | Number of shares making up the share capital | % of ownership | Number of theoretical voting rights | % of theoretical voting rights | ||||
| Sub-total funds managed by Truffle Capital | 2,677,890 | 41.6% | 4,851,937 | 53.8% | ||||
| Furui | 1,208,651 | 18.8% | 1,208,651 | 13.4% | ||||
| Other registered shares | 437,095 | 6.8% | 845,636 | 9.4% | ||||
| Treasury shares | 9,021 | 0.1% | 9,021 | 0.1% | ||||
| Other Public | 2,108,372 | 32.7% | 2,108,372 | 23.4% | ||||
| Total | 6,441,029 | 100.0% | 9,023,617 | 100.0% | ||||
All information relating to the shareholders’ general meeting is available at Theraclion’s website, www.theraclion.fr, in the Investors / Documentation / General Meeting section. Voting details for each resolution will also be available in that section in accordance with statutory and regulatory requirements.
About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.
Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402
Theraclion
David Caumartin
CEO
Tel.: +33 (0)1 55 48 90 70
david.caumartin@theraclion.com
or
Kalima
Press Relations
Florence Calba
Tel.: + 33 (0)1 44 90 82 54
fcalba@kalima-rp.fr
or
The Ruth Group (U.S.)
Investor Relations / Public Relations
Robert Flamm / Kirsten Thomas
+1 646-536-7017 / +1 508-280-6592
rflamm@theruthgroup.com / thomas@theruthgroup.com
